-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 22, 2024

Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Author(s)Robert O'Brien, RPh, Diana I. Brixner, PhD, RPh, Ashley Peterson, MHA

Medical experts identify key stakeholders within health plans who collaborate in the decision-making process for coverage, access, and benefit design related to prescription digital therapeutics.

Episodes in this series

Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"

EP. 1 Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"

EP. 2 Payer Needs and Strategies for Evaluating and Covering PDTs

A panel of 4 experts on PDTs

EP. 3 Payers Review Process and Effective Strategies for PDT Coverage

A panel of 4 experts on PDTs

EP. 4 Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Video 5 - "Dawn of the Age of Adopting PDTs"

EP. 5 Dawn of the Age of Adopting PDTs

Video 6 -"Identifying the Most Impactful Disease Areas and Patient Populations for PDTs"

EP. 6 Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

4 KOLs discuss PDTs

EP. 7 Evolving Commercialization and Distribution Models for PDTs

4 KOLs discuss PDTs

EP. 8 Promoting Appropriate PDT Prescribing Through Provider Education and Support

A panel of 4 experts on PDTs

EP. 9 Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

A panel of 4 experts on PDTs

EP. 10 Optimizing Benefit Design and Implementation for Improved PDT Access

A panel of 4 experts on PDTs

EP. 11 PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Little boy using in haler. | Image credit: WavebreakmediaMicro_stock.adobe.com

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

BySabrina McCrear

June 24th 2026

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

ByBrooke McCormick

June 23rd 2026

Joseph K. Han, MD

How Upstream Biologics Could Transform CRSwNP Care: Joseph K. Han, MD

BySabrina McCrear,Joseph K. Han, MD

June 23rd 2026

X-ray scan with patient. | Image Credit: DraganaGordic_AdobeStock.jpeg

Familial Pulmonary Fibrosis Linked to Faster Lung Function Decline, UIP Pattern

BySabrina McCrear

June 23rd 2026

Ocrelizumab | Image credit: Semi - stock.adobe.com

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS

ByJulia Bonavitacola

June 23rd 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

ATTR-CM Incidence, Prevalence Rose Sharply in the US

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Zanubrutinib Tops Rivals in Real-World CLL Survival Study